WallStSmart

Merck & Company Inc (MRK)vsScholar Rock Holding Corp (SRRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

SRRK

Avoid

23

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 5.0
Piotroski: 1/9Altman Z: -5.63
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-62.3%)

Margin of Safety

-62.3%

Fair Value

$81.23

Current Price

$129.79

$48.56 premium

UndervaluedFair: $81.23Overvalued

Intrinsic value data unavailable for SRRK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$307.25B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

SRRK0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
35.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SRRK4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : SRRK

SRRK has a balanced fundamental profile.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : SRRK

The primary concerns for SRRK are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

SRRK carries more volatility with a beta of 0.68 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (50/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Scholar Rock Holding Corp

HEALTHCARE · BIOTECHNOLOGY · USA

Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which protein growth factor signaling plays a critical role. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?